公开(公告)号：US10556948B2

公开(公告)日：2020-02-11

申请号：US15364612

申请日：2016-11-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Mohan Srinivasan ,  Shrikant Deshpande ,  Qihong Zhao ,  Huadong Sun ,  Ginger Rakestraw ,  Guodong Chen ,  Richard Y. Huang ,  Steven Sheriff ,  Cristian Rodriguez ,  John P. Throup ,  Rose A. Dibella

IPC: C07K16/00 ,  C12P21/08 ,  C07K16/24 ,  A61K9/00 ,  C07K1/00 ,  A61K39/00

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

公开(公告)号：US20240228664A9

公开(公告)日：2024-07-11

申请号：US18357007

申请日：2023-07-21

Applicant: Bristol-Myers Squibb Company

Inventor： Lin Hui Su ,  Ekaterina Deyanova ,  Burce Ergel Gurbuzbalaban ,  Mariana Nacht ,  Samantha Elaine Pace ,  Yun Wang ,  Qing Xiao ,  Ramakrishna Chandran ,  Shailesh Dudhgaonkar ,  Michael Louis Doyle ,  Michael Gilman ,  Richard Huang ,  Akbar Nayeem ,  Alok Sharma ,  Qihong Zhao

IPC: C07K16/40 ,  A01N1/02 ,  A61K45/06 ,  A61K47/68 ,  A61K49/00 ,  A61P19/02 ,  A61P37/06

CPC classification number: C07K16/40 ,  A01N1/0226 ,  A61K45/06 ,  A61K47/6871 ,  A61K49/0002 ,  A61P19/02 ,  A61P37/06

Abstract: The present application relates to particular anti-PAD4 (peptidyl arginine deiminase 4) antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies.

公开(公告)号：US20240132622A1

公开(公告)日：2024-04-25

申请号：US18357007

申请日：2023-07-20

Applicant: Bristol-Myers Squibb Company

Inventor： Lin Hui Su ,  Ekaterina Deyanova ,  Burce Ergel Gurbuzbalaban ,  Mariana Nacht ,  Samantha Elaine Pace ,  Yun Wang ,  Qing Xiao ,  Ramakrishna Chandran ,  Shailesh Dudhgaonkar ,  Michael Louis Doyle ,  Michael Gilman ,  Richard Huang ,  Akbar Nayeem ,  Alok Sharma ,  Qihong Zhao

IPC: C07K16/40 ,  A01N1/02 ,  A61K45/06 ,  A61K47/68 ,  A61K49/00 ,  A61P19/02 ,  A61P37/06

CPC classification number: C07K16/40 ,  A01N1/0226 ,  A61K45/06 ,  A61K47/6871 ,  A61K49/0002 ,  A61P19/02 ,  A61P37/06

Abstract: The present application relates to particular anti-PAD4 (peptidyl arginine deiminase 4) antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies.

公开(公告)号：US11708405B2

公开(公告)日：2023-07-25

申请号：US16728757

申请日：2019-12-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Mohan Srinivasan ,  Shrikant Deshpande ,  Qihong Zhao ,  Huadong Sun ,  Ginger Rakestraw ,  Guodong Chen ,  Richard Y. Huang ,  Steven Sheriff ,  Cristian Rodriguez ,  John P. Throup ,  Rose A. Dibella

IPC: A61K39/395 ,  C07K16/24 ,  A61K47/68 ,  A61K9/00 ,  C07K16/00 ,  A61K39/00

CPC classification number: C07K16/24 ,  A61K9/0019 ,  A61K47/6845 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

公开(公告)号：US20220160718A1

公开(公告)日：2022-05-26

申请号：US17581481

申请日：2022-01-21

Applicant: Bristol-Myers Squibb Company

Inventor： Qihong Zhao ,  Joseph Fargnoli ,  Murali Gururajan ,  Susan Wee

IPC: A61K31/53 ,  C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61P35/04 ,  A61K9/00 ,  A61K45/06

Abstract: The invention is directed to methods of treating cancer in subjects with a combination comprising a CCR2/5 dual antagonist, such as N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide; a monoclonal antibody, such as nivolumab; and/or chemotherapy.

公开(公告)号：US20190224205A1

公开(公告)日：2019-07-25

申请号：US16253353

申请日：2019-01-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Qihong Zhao ,  Joseph Fargnoli ,  Murali Gururajan ,  Susan Wee

IPC: A61K31/53 ,  A61K9/00 ,  A61K45/06 ,  C07K16/28 ,  A61P35/04

Abstract: The invention is directed to methods of treating cancer in subjects with a combination comprising a CCR2/5 dual antagonist, such as N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide; a monoclonal antibody, such as nivolumab; and/or chemotherapy.